|
AstraZeneca PLC on Wednesday said its Enhertu drug achieved statistically significant overall survival in breast cancer patients in a recent trial.
The Cambridge-based pharmaceutical company develops Enhertu, a specifically engineered HER2-directed antibody drug conjugate, with its Tokyo-based partner Daiichi Sankyo Co Ltd.
AstraZeneca said results from its Destiny-Breast03 Phase 3 trial showed that Enhertu demonstrated a 36% reduction in the risk of death in patients with HER2-positive metastatic breast cancer, compared to trastuzumab emtansine, which is another cancer drug.
Around 77% of patients were alive in the Enhertu arm at two years, compared to 70% of patients treated with trastuzumab emtansine. AstraZeneca said the observed survival benefit was consistent across all analysed subgroups.
It added that the recent trial showed Enhertu continues to demonstrate an improvement in progression-free survival, with a 22-month improvement in median progression-free survival over trastuzumab emtansine.
The updated results for Destiny-Breast03 showing that Enhertu extends patients’
|
